These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29535371)

  • 1. The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis.
    Watts L; Karaderi T; Roberts A; Appleton L; Wordsworth T; Cohen C; Wordsworth P; Vecellio M
    Genes Immun; 2019 Feb; 20(2):167-171. PubMed ID: 29535371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients.
    Madsen OR; Rytter A; Hansen LB; Suetta C; Egsmose C
    Clin Rheumatol; 2010 Aug; 29(8):849-54. PubMed ID: 20306214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.
    Lord PA; Farragher TM; Lunt M; Watson KD; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2010 Mar; 49(3):563-70. PubMed ID: 20032223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of genetic association between TNFRSF1A encoding the p55 tumour necrosis factor receptor, and ankylosing spondylitis in UK Caucasians.
    Karaderi T; Pointon JJ; Wordsworth TW; Harvey D; Appleton LH; Cohen CJ; Farrar C; Harin A; Brown MA; Wordsworth BP;
    Clin Exp Rheumatol; 2012; 30(1):110-3. PubMed ID: 22272576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis.
    Comabella M; Caminero AB; Malhotra S; Agulló L; Fernández O; Reverter F; Vandenbroeck K; Rodríguez-Antigüedad A; Matesanz F; Izquierdo G; Urcelay E; López-Larios A; Sánchez A; Otero S; Tintoré M; Montalban X
    Neurology; 2013 May; 80(22):2010-6. PubMed ID: 23624563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of fatigue, pain, patient global assessment and the Bath Ankylosing Spondylitis Functional Index (BASFI) in spondyloarthropathy patients with stable disease according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
    Madsen OR
    Rheumatol Int; 2018 Mar; 38(3):425-432. PubMed ID: 29299630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G).
    Jones SD; Steiner A; Garrett SL; Calin A
    Br J Rheumatol; 1996 Jan; 35(1):66-71. PubMed ID: 8624626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Iranian versions of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Patient Acceptable Symptom State (PASS) in patients with ankylosing spondylitis.
    Bidad K; Fallahi S; Mahmoudi M; Jamshidi A; Farhadi E; Meysamie A; Nicknam MH
    Rheumatol Int; 2012 Nov; 32(11):3613-8. PubMed ID: 22101612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically determined high activities of the TNF-alpha, IL23/IL17, and NFkB pathways were associated with increased risk of ankylosing spondylitis.
    Sode J; Bank S; Vogel U; Andersen PS; Sørensen SB; Bojesen AB; Andersen MR; Brandslund I; Dessau RB; Hoffmann HJ; Glintborg B; Hetland ML; Locht H; Heegaard NH; Andersen V
    BMC Med Genet; 2018 Sep; 19(1):165. PubMed ID: 30208882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychometric evaluation of the Moroccan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in patients with ankylosing spondylitis.
    Rostom S; Benbouaaza K; Amine B; Bahiri R; Ibn Yacoub Y; Ali Ou Alla S; Abouqal R; Hajjaj-Hassouni N
    Clin Rheumatol; 2010 Jul; 29(7):781-8. PubMed ID: 20383548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is disease severity in ankylosing spondylitis genetically determined?
    Hamersma J; Cardon LR; Bradbury L; Brophy S; van der Horst-Bruinsma I; Calin A; Brown MA
    Arthritis Rheum; 2001 Jun; 44(6):1396-400. PubMed ID: 11407700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications.
    Bitoun S; Miceli-Richard C; Verstuyft C; Juge PA; Dieudé P; Berthelot JM; Richez C; Cauquil C; Sordet C; Melac-Ducamp S; Gossec L; Bouvard B; Dernis E; Houvenagel E; Boutry-Bacle MA; Mariette X; Seror R
    Ann Rheum Dis; 2018 Dec; 77(12):1835-1836. PubMed ID: 30030263
    [No Abstract]   [Full Text] [Related]  

  • 15. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
    Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
    BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported Flares in Ankylosing Spondylitis: A Cross-sectional Analysis of 234 Patients.
    Jacquemin C; Maksymowych WP; Boonen A; Gossec L
    J Rheumatol; 2017 Apr; 44(4):425-430. PubMed ID: 27980007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.
    Gregory AP; Dendrou CA; Attfield KE; Haghikia A; Xifara DK; Butter F; Poschmann G; Kaur G; Lambert L; Leach OA; Prömel S; Punwani D; Felce JH; Davis SJ; Gold R; Nielsen FC; Siegel RM; Mann M; Bell JI; McVean G; Fugger L
    Nature; 2012 Aug; 488(7412):508-511. PubMed ID: 22801493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of NLRP3 and TNFRSF1A polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept.
    Zhao S; Chen H; Wu G; Zhao C
    J Clin Lab Anal; 2017 Nov; 31(6):. PubMed ID: 28116820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFR1 -383 A˃C polymorphism and ankylosing spondylitis in a Russian Caucasian population: a preliminary study.
    Mordovskii V; Semenchukov A; Nikulina SY; Salmina AB; Chernova A; Kapustina E; Kents A; Ohapkina A; Moskaleva E; Maltese PE; Convertini P; Bertelli M
    Genet Mol Res; 2017 Mar; 16(1):. PubMed ID: 28363009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
    Glintborg B; Østergaard M; Krogh NS; Tarp U; Manilo N; Loft AG; Hansen A; Schlemmer A; Fana V; Lindegaard HM; Nordin H; Rasmussen C; Ejstrup L; Jensen DV; Petersen PM; Hetland ML
    Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.